BMS-202 (PD1-PDL1 inhibitor 2) is an inhibitor of the PD-1 (Programmed death- 1) /PD-Ll (Programmed death-ligand 1) protein/protein interaction.

PD1-PDL1-IN 1 TFA (compound 16) is a potent inhibitor of programmed cell death 1 (PD-1), functioning as an immune modulator [1].

PDL-1 cpd 10 is a novel small molecule PD-L1 inhititor.

PD1-PDL1-IN 2 (ZE132) is a potent, selective inhibitor of PD-1/PD-L1, exhibiting significant anti-tumor activity in vivo. It enhances cytotoxic T-cell tumor infiltration and stimulates IL-2 expression, while also strongly inhibiting TGF-β [1] mRNA expression, showcasing its comprehensive immunotherapeutic potential.

Gilvetmab, a potent caninized anti-PD-1 monoclonal antibody, effectively inhibits the interaction between PD-1 and its ligand PDL-1 [1].

The Immuno-Oncology Screening Library consists of 2 plates and contains more than 90 cancer and immunology-associated compounds in a 96-well Matrix tube rack format as 10 mM stock solutions in DMSO. This library includes a variety of immuno-oncology target modulators, including but not limited to, adenosine, CCR, CXCR, and TLR agonists and antagonists, BTK, PI3K, VEGFR, and BRAF inhibitors, PD-1/PDL-1 interaction inhibitors, and HDAC inhibitors. Please review the product insert for a full list of targets. Stability data is not available for the compounds as supplied in the screening library.